U.S. Biotech Stock News

In recent months, DexCom has seen mixed reactions from Wall Street as Morgan Stanley upgraded the stock, Evercore ISI initiated coverage with a more cautious stance, the FDA cleared its Dexcom Smart Basal insulin dosing optimizer for adults with Type 2 diabetes, and multiple securities class action lawsuits were filed over alleged misstatements about G6 and G7 device reliability and manufacturing. This combination of regulatory progress, differing analyst views, and legal scrutiny...

Earlier this month, Polestar Automotive Holding UK PLC raised US$300.0 million by selling 15,511,892 Class A ADSs via a PIPE at US$19.34 each, while also securing access to a US$600.0 million term loan facility from Geely Sweden Automotive Investment AB for general corporate purposes. The combination of fresh equity and a sizable short-term loan with an option for share conversion materially strengthens Polestar’s funding runway but also introduces dilution and capital structure...

In December 2025, Pacira BioSciences announced it had joined the European Innovative Health Initiative-funded PROBE Consortium, a global public-private effort using AI and a regulation-compliant big-data network spanning more than 70 million osteoarthritis patient records to improve OA diagnosis, treatment evaluation, and shared decision-making. This move directly aligns Pacira’s non-opioid analgesics, OA-focused products, and PCRX-201 gene therapy program with a large-scale infrastructure...

Science Applications International Corporation recently appointed Ravi Dankanikote as Chief Growth Officer, reporting to interim CEO Jim Reagan and tasked with leading the company’s enterprise growth strategy and go-to-market approach. This leadership change comes shortly after SAIC delivered a strong quarter with earnings surpassing analyst expectations and full-year EPS guidance raised more than peers, underscoring management’s focus on profitability and growth execution. We’ll now examine...

In recent weeks, analysts reiterated positive views on Viking Therapeutics after competitor Eli Lilly reported supportive Phase 3 results for a similar oral obesity therapy, reinforcing confidence in Viking’s lead candidate VK2735 and its broader metabolic pipeline. This combination of bullish analyst coverage and external clinical validation highlights how Viking, still without approved products, is increasingly viewed as a potential participant in large obesity and NASH markets. We’ll now...

Earlier in December 2025, F5 announced an expanded collaboration with NetApp to improve high-performance AI data delivery and strengthen post-quantum security for enterprise S3 storage environments. The partnership’s focus on quantum-resistant encryption and resilient AI data pipelines highlights how NetApp is aligning its storage platform with emerging cybersecurity and AI infrastructure demands. We’ll now explore how this expanded F5 collaboration, especially its post-quantum security...

Oracle (ORCL) has quietly outpaced the broader software sector over the past year, and with shares near $198 investors are asking a simple question: is the recent run justified or stretched? See our latest analysis for Oracle. That question is more than fair given the backdrop, with a strong 7 day share price return and a solid year to date share price gain sitting alongside an impressive multi year total shareholder return that suggests long term momentum is still very much intact, even if...

Chipotle Mexican Grill (CMG) has quietly outperformed the broader market over the past month, climbing about 20% even as its year to date performance remains sharply negative and longer term returns look mixed. See our latest analysis for Chipotle Mexican Grill. That 19.9% 30 day share price return has only just started to chip away at a tough year to date slide and weak 1 year total shareholder return, suggesting momentum is recovering rather than fully reset. If Chipotle’s rebound has you...

Invitation Homes Inc. previously declared a quarterly cash dividend of US$0.30 per share, a 3.4% increase from US$0.29, payable on or before January 16, 2026, to shareholders of record as of December 23, 2025. This higher payout signals management’s confidence in the company’s cash generation and reinforces its emphasis on returning capital to shareholders through regular dividends. Next, we’ll examine how this higher recurring dividend influences Invitation Homes’ income profile within its...

AngloGold Ashanti (NYSE:AU) has been riding a clear shift in fundamentals, with higher gold prices, a 17% jump in Q3 production, and stronger free cash flow reshaping how investors think about the stock. See our latest analysis for AngloGold Ashanti. Those operational gains are clearly feeding into sentiment, with a 29.65% 3 month share price return and a 299.62% 1 year total shareholder return pointing to strong, building momentum rather than a one off spike. If AngloGold’s run has you...

Oceaneering International has announced that Michael W. Sumruld will become Senior Vice President and Chief Financial Officer on January 1, 2026, succeeding retiring CFO Alan R. Curtis, who will remain as an adviser to support the handover. This planned CFO transition, with Curtis staying involved in an advisory role, points to an emphasis on continuity in financial oversight and corporate decision‑making. We’ll now examine how this planned CFO handover and emphasis on continuity could...

ReNew Energy Global (NasdaqGS:RNW) just inked a long term deal with Google for a 150 MW solar project in Rajasthan, a fresh signal that big tech demand is driving its next growth leg. See our latest analysis for ReNew Energy Global. Yet despite this high profile Google deal and the recent decision to walk away from a planned acquisition, the stock's 30 day share price return of minus 27.26 percent and 1 year total shareholder return of minus 20.95 percent show that sentiment has been weak,...

Eli Lilly (LLY) just checked several big boxes at once, with strong Phase 3 data for its oral GLP-1 orforglipron, encouraging breast cancer results for Inluriyo, and a multibillion dollar U.S. manufacturing build out. See our latest analysis for Eli Lilly. All of this is showing up in the tape, with Eli Lilly’s share price up 44.11% over the past 90 days and a five year total shareholder return of 581.29%, signaling strong momentum behind the $1,076.48 stock. If Lilly’s recent performance has...

Adecoagro S.A. recently completed a US$300.00 million follow-on equity offering, issuing a total of 41,379,311 common shares at US$7.25 each, including a smaller tranche sold at a discount of US$0.3263 per share. This sizeable capital raise meaningfully increases the company’s share count, which can affect existing shareholders through dilution while providing fresh funding for corporate priorities. Next, we’ll examine how this sizeable follow-on equity issuance could reshape Adecoagro’s...

Leonardo DRS (DRS) just cleared two big milestones: successfully running its new multi channel, software defined radio in orbit and signing a cooperation memorandum with Saudi Arabia’s Ministry of Defense on ground combat vehicle technology. See our latest analysis for Leonardo DRS. Those breakthroughs are landing at a time when the stock is catching its breath, with a 7.38% year to date share price return and a powerful 167.05% three year total shareholder return that still signals long term...

In recent days, S2 Resources completed the sale of its Fosterville exploration licence EL007795 to a 100% owned Agnico Eagle Mines subsidiary, with Agnico Eagle paying A$17,000,000 through Southern Star Exploration as it continues expanding its international gold portfolio across stable mining jurisdictions. At the same time, Agnico Eagle’s momentum-focused Zacks Rank #1 rating, supported by upward earnings estimate revisions and recent outperformance in the gold mining industry, has drawn...

In December 2025, Labaton Keller Sucharow LLP announced that StoneCo and lead plaintiff Indiana Public Retirement System reached a proposed US$26,750,000 settlement to resolve securities litigation covering investors who bought StoneCo shares between May 27, 2020 and November 16, 2021, with a court hearing set for February 27, 2026. The proposed settlement, which StoneCo accepts without admitting wrongdoing, could reduce legal uncertainty for investors while formalizing the scope of past...

In December 2025, Perfect Corp. announced it will showcase a new generation of AI beauty agents and a modular, consumption-based API suite at CES 2026, aimed at powering personalized, cross-channel experiences for brands of all sizes. The move signals a push to become an infrastructure provider for beauty and retail AI, shifting from standalone apps toward developer-first tools that can embed Perfect’s technology across e-commerce, mobile, and in-store journeys. We’ll now examine how...

Arcus Biosciences (RCUS) just shook up its pipeline strategy by scrapping the high profile Phase 3 STAR-221 gastric cancer trial after an interim look showed no survival benefit for its domvanalimab combo. See our latest analysis for Arcus Biosciences. Despite the headline setback in gastric cancer, investors seem to be looking through the domvanalimab news to Arcus Biosciences longer term pipeline potential. The share price is $23.22, with a powerful 90 day share price return of 87.41...

Earlier this month, CBRE announced a series of leadership changes effective January 1, 2026, promoting Andy Glanzman to CEO of Real Estate Investments, elevating Adam Nims to CEO of Trammell Crow Company, and appointing Adam Saphier as Global COO of Advisory Services, while Danny Queenan moves into an Executive Group President role. These promotions consolidate oversight of CBRE’s development and investment management arms under Glanzman and tighten global operational control in Advisory...

On December 19, 2025, Okta expanded its Board of Directors from 10 to 11 members, appointing industry veterans Rob Bernshteyn and Paul Sagan as independent directors while confirming the earlier resignation of Mary Agnes (Maggie) Wilderotter for personal reasons unrelated to the company. By adding leaders with long experience in SaaS, cybersecurity and enterprise software governance, Okta is reinforcing its push to be a neutral identity partner in an era where AI-driven security and...

Earlier this month, Cohen & Steers, Inc. expanded its actively managed ETF lineup by launching the Cohen & Steers Infrastructure Opportunities Active ETF (CSIO) and the Cohen & Steers Short Duration Preferred and Income Active ETF (CSSD), which began trading on NYSE Arca. By adding infrastructure and short-duration preferred income ETFs to its existing real assets platform, the firm is signaling a stronger push to package its real estate and alternative income expertise in lower-cost,...

In December 2025, Darling Ingredients announced a definitive agreement with Tessenderlo Group to combine their Rousselot and PB Leiner collagen and gelatin businesses into a new joint company with about US$1.50 billion in annual revenue and 200,000 metric tons of capacity across 22 global facilities, while also expanding 2025 sales of renewable fuel production tax credits from its Diamond Green Diesel joint venture to US$235 million. This combination of a large-scale, no-cash-required...

Ocugen, Inc. recently presented at the Oppenheimer Movers in Rare Disease Summit in New York City on 11 December 2025, with Co-Founder, CEO and Chairman Shankar Musunuri highlighting the company’s rare disease focus. This appearance gives Ocugen a platform to spotlight its gene and cell therapy pipeline to an audience focused on rare diseases, potentially shaping expectations around its development path and partnering opportunities. We’ll now examine how this rare disease summit appearance...